Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: N. Mani Subramanian who wrote (3648)	1/22/1998 12:50:00 PM
From: Peter Singleton	Respond to of 6136

the physician survey below rates the Merck sales force top in infectious disease ... maybe an indication of why MRK continues to sell so much Crixivan despite the apparent superiority of Viracept. a tough competitor ... Pfizer Labs Remains Top Sales Force with Doctors NEWTOWN, Pa.--(BW HealthWire)--Jan. 22, 1998-- Pharmaceutical Sales Forces Most Valued by Physicians 1. Pfizer Labs 2. SmithKline Beecham 3. Wyeth-Ayerst 4. Merck 5. Glaxo 6. Bristol-Myers Squibb 7. SmithKline & French 8. Parke-Davis 9. Eli Lilly 10. Schering Source: Scott-Levin, Sales Force Structures & Strategies 1997-98 For the third straight year, the Pfizer Labs sales force was rated first collectively by U.S. physicians in nine key specialty groups: general/family practitioners, internal medicine specialists, cardiologists, obstetricians/gynecologists, pediatricians, general surgeons, orthopedic surgeons, gastroenterologists and psychiatrists. Pfizer Labs also finished No. 1 among general practitioners for the third consecutive year. A major new product launch and a high-profile co-promotional arrangement helped Pfizer maintain its top position among the nine core specialty groups. In 1997, the company introduced the Alzheimer's disease therapy Aricept and began co-promoting Lipitor, Parke-Davis' powerful new cholesterol reducer. To help support these new launches, Pfizer added the 650-rep Powers field force to its already formidable sales organization. New indications for the antidepressant Zoloft also boosted Pfizer's reputation in 1997. The brand was approved to treat panic disorder in adults and obsessive-compulsive disorder in children as young as 6. Zoloft previously was cleared to treat OCD in adults. These rankings come from Sales Force Structures & Strategies 1997-98, the 10th edition of the longest-running study of pharmaceutical sales forces, performed annually by the health care consulting firm Scott-Levin. Twenty-eight physician specialty groups were surveyed for this year's study. Other leaders among sales forces were Merck, rated first by internal medicine specialists, cardiologists, rheumatologists and infectious disease specialists; Wyeth-Ayerst, tops with OB/GYNs, orthopedic surgeons and physical medicine and rehabilitation specialists; SmithKline Beecham, No. 1 among general surgeons and neurosurgeons; Schering, first with allergists and otorhinolaryngologists; Astra Merck, the favorite among gastroenterologists; Lilly, ranked first by psychiatrists; and Ross, tops with pediatricians For more information on the study, contact Art McKee at 215/860-0440; fax: 215/860-5477; e-mail: art@scottlevin.com. CONTACT: Scott-Levin, Newtown Art McKee, 215/860-0440 scottlevin.com KEYWORD: PENNSYLVANIA BW1066 JAN 22,1998